Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer.

Frontiers in oncology·2026
Same author

Reply to: Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.

Cancer discovery·2026
Same author

Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).

BMC cancer·2025
Same author

Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer.

Cancers·2025

Related Experiment Video

Updated: Apr 7, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

940

Hilar cholangiocarcinoma: expert consensus statement.

John C Mansour1, Thomas A Aloia2, Christopher H Crane3

  • 1Division of Surgical Oncology, University of Texas Southwestern, Dallas, TX, USA.

HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|July 15, 2015
PubMed
Summary
This summary is machine-generated.

Management of hilar cholangiocarcinoma requires a multidisciplinary approach. Guidelines emphasize resection for resectable cases and trimodal therapy or chemotherapy for unresectable or advanced disease, optimizing patient survival and palliation.

More Related Videos

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

181
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.6K

Related Experiment Videos

Last Updated: Apr 7, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

940
Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

181
Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma
09:19

Robotic Taj Mahal Hepatectomy for Hilar Cholangiocarcinoma

Published on: July 14, 2022

4.6K

Area of Science:

  • Hepatobiliary Surgery
  • Surgical Oncology
  • Gastroenterology

Background:

  • Hilar cholangiocarcinoma (Bile duct cancer) management is complex.
  • A coordinated, multidisciplinary approach is crucial for survival and palliation.

Purpose of the Study:

  • Establish practice guidelines for hilar cholangiocarcinoma.
  • Develop consensus statements on its management.

Main Methods:

  • Consensus meeting of American Hepato-Pancreato-Biliary Association (AHPBA) experts.
  • Review of current evidence on hilar cholangiocarcinoma management.
  • Development of guidelines and consensus statements.

Main Results:

  • Multidisciplinary care is essential for hilar cholangiocarcinoma.
  • Resection is the ideal treatment for resectable tumors.
  • Trimodal therapy (chemotherapy, radiation, liver transplant) is for unresectable cases.
  • Percutaneous transhepatic biliary drainage and portal vein embolization are key supportive measures.
  • Post-resection chemoradiation and first-line gemcitabine/cisplatin chemotherapy are recommended for specific patient groups.

Conclusions:

  • Optimal hilar cholangiocarcinoma treatment necessitates a coordinated, multidisciplinary strategy.
  • Guidelines address diagnosis, staging, resectable and unresectable disease management, and palliative care.
  • Evidence supports specific chemotherapeutic regimens for advanced or recurrent disease.